HomeCompareKRTX vs VICI

KRTX vs VICI: Dividend Comparison 2026

KRTX yields 0.61% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $968.3K in total portfolio value
10 years
KRTX
KRTX
● Live price
0.61%
Share price
$329.83
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.5K
Annual income
$63.08
Full KRTX calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — KRTX vs VICI

📍 VICI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKRTXVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KRTX + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KRTX pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KRTX
Annual income on $10K today (after 15% tax)
$51.54/yr
After 10yr DRIP, annual income (after tax)
$53.62/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $529,718.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KRTX + VICI for your $10,000?

KRTX: 50%VICI: 50%
100% VICI50/50100% KRTX
Portfolio after 10yr
$504.7K
Annual income
$311,662.20/yr
Blended yield
61.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

KRTX
Analyst Ratings
16
Buy
9
Hold
Consensus: Buy
Price Target
$257.50
-21.9% upside vs current
Range: $150.00 — $330.00
Altman Z
91.1
Piotroski
1/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KRTX buys
0
VICI buys
0
No recent congressional trades found for KRTX or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKRTXVICI
Forward yield0.61%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$20.5K$988.8K
Annual income after 10y$63.08$623,261.32
Total dividends collected$620.00$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$257.50$31.60

Year-by-year: KRTX vs VICI ($10,000, DRIP)

YearKRTX PortfolioKRTX Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$10,761$60.64$11,368$948.43$607.00VICI
2$11,575$60.98$13,339$1,493.16$1.8KVICI
3$12,446$61.30$16,326$2,426.21$3.9KVICI
4$13,379$61.61$21,123$4,112.15$7.7KVICI
5$14,378$61.89$29,379$7,368.23$15.0KVICI
6$15,446$62.16$44,804$14,191.64$29.4KVICI
7$16,590$62.41$76,658$29,972.12$60.1KVICI
8$17,814$62.65$150,894$71,015.81$133.1KVICI
9$19,124$62.87$350,814$193,582.47$331.7KVICI
10$20,525$63.08$988,809$623,261.32$968.3KVICI

KRTX vs VICI: Complete Analysis 2026

KRTXStock

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Full KRTX Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this KRTX vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KRTX vs SCHDKRTX vs JEPIKRTX vs OKRTX vs KOKRTX vs MAINKRTX vs NNNKRTX vs EPRTKRTX vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.